Literature DB >> 21931474

The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.

David J Reeves, Amanda K Quebe, Ranita Patel.   

Abstract

Year:  2011        PMID： 21931474      PMCID： PMC3171811     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  11 in total

Review 1.  American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Authors:  J Douglas Rizzo; Melissa Brouwers; Patricia Hurley; Jerome Seidenfeld; Murat O Arcasoy; Jerry L Spivak; Charles L Bennett; Julia Bohlius; Darren Evanchuk; Matthew J Goode; Ann A Jakubowski; David H Regan; Mark R Somerfield
Journal:  Blood       Date:  2010-10-25       Impact factor: 22.113

Review 2.  Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Authors:  Julia Bohlius; Simon Langensiepen; Guido Schwarzer; Jerome Seidenfeld; Margaret Piper; Charles Bennett; Andreas Engert
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

3.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

Review 4.  Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

Authors:  Julia Bohlius; Jayne Wilson; Jerome Seidenfeld; Margaret Piper; Guido Schwarzer; Josie Sandercock; Sven Trelle; Olaf Weingart; Sue Bayliss; Benjamin Djulbegovic; Charles L Bennett; Simon Langensiepen; Chris Hyde; Andreas Engert
Journal:  J Natl Cancer Inst       Date:  2006-05-17       Impact factor: 13.506

5.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

Authors:  Michael Henke; Roland Laszig; Christian Rübe; Ulrich Schäfer; Klaus-Dieter Haase; Burkhard Schilcher; Stephan Mose; Karl T Beer; Ulrich Burger; Chris Dougherty; Hermann Frommhold
Journal:  Lancet       Date:  2003-10-18       Impact factor: 79.321

6.  Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

Authors:  Michael Hedenus; Magnus Adriansson; Jesus San Miguel; Mark H H Kramer; Martin R Schipperus; Eeva Juvonen; Kerry Taylor; Andrew Belch; Albert Altés; Giovanni Martinelli; David Watson; James Matcham; Gregory Rossi; Timothy J Littlewood
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

7.  Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.

Authors:  Gillian Thomas; Shamshad Ali; Frank J P Hoebers; Kathleen M Darcy; William H Rodgers; Malti Patel; Ovardia Abulafia; Joseph A Lucci; Adrian C Begg
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

8.  Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Robert E Smith; Matti S Aapro; Heinz Ludwig; Tamás Pintér; Martin Smakal; Tudor E Ciuleanu; Li Chen; Tom Lillie; John A Glaspy
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

Review 9.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

Authors:  Charles L Bennett; Samuel M Silver; Benjamin Djulbegovic; Athena T Samaras; C Anthony Blau; Kara J Gleason; Sara E Barnato; Kathleen M Elverman; D Mark Courtney; June M McKoy; Beatrice J Edwards; Cara C Tigue; Dennis W Raisch; Paul R Yarnold; David A Dorr; Timothy M Kuzel; Martin S Tallman; Steven M Trifilio; Dennis P West; Stephen Y Lai; Michael Henke
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

10.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Michael Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Dirk Rades; David P Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Mitchell Machtay; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
View more
  3 in total

1.  Impact of a Patient Blood Management Program and an Outpatient Anemia Management Protocol on Red Cell Transfusions in Oncology Inpatients and Outpatients.

Authors:  Irwin Gross; Kevin M Trentino; Astrid Andreescu; Rhonda Pierson; Richard A Maietta; Shannon Farmer
Journal:  Oncologist       Date:  2016-02-10

Review 2.  Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.

Authors:  Monica Epstein; Candis Morrison
Journal:  Semin Oncol       Date:  2022-02-10       Impact factor: 5.385

3.  End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

Authors:  Shamia Hoque; Brian J Chen; Martin W Schoen; Kenneth R Carson; Jesse Keller; Bartlett J Witherspoon; Kevin B Knopf; Y Tony Yang; Benjamin Schooley; Chadi Nabhan; Oliver Sartor; Paul R Yarnold; Paul Ray; Laura Bobolts; William J Hrushesky; Michael Dickson; Charles L Bennett
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.